These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

441 related articles for article (PubMed ID: 29854817)

  • 21. The gut microbiome as a target for prevention and treatment of hyperglycaemia in type 2 diabetes: from current human evidence to future possibilities.
    Brunkwall L; Orho-Melander M
    Diabetologia; 2017 Jun; 60(6):943-951. PubMed ID: 28434033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural Alteration of Gut Microbiota during the Amelioration of Human Type 2 Diabetes with Hyperlipidemia by Metformin and a Traditional Chinese Herbal Formula: a Multicenter, Randomized, Open Label Clinical Trial.
    Tong X; Xu J; Lian F; Yu X; Zhao Y; Xu L; Zhang M; Zhao X; Shen J; Wu S; Pang X; Tian J; Zhang C; Zhou Q; Wang L; Pang B; Chen F; Peng Z; Wang J; Zhen Z; Fang C; Li M; Chen L; Zhao L
    mBio; 2018 May; 9(3):. PubMed ID: 29789365
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus.
    Su B; Liu H; Li J; Sunli Y; Liu B; Liu D; Zhang P; Meng X
    J Diabetes; 2015 Sep; 7(5):729-39. PubMed ID: 25327485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting the gastrointestinal tract to treat type 2 diabetes.
    Bauer PV; Duca FA
    J Endocrinol; 2016 Sep; 230(3):R95-R113. PubMed ID: 27496374
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity.
    Remely M; Aumueller E; Merold C; Dworzak S; Hippe B; Zanner J; Pointner A; Brath H; Haslberger AG
    Gene; 2014 Mar; 537(1):85-92. PubMed ID: 24325907
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacologic and Nonpharmacologic Therapies for the Gut Microbiota in Type 2 Diabetes.
    Caesar R
    Can J Diabetes; 2019 Apr; 43(3):224-231. PubMed ID: 30929665
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment.
    Gu Y; Wang X; Li J; Zhang Y; Zhong H; Liu R; Zhang D; Feng Q; Xie X; Hong J; Ren H; Liu W; Ma J; Su Q; Zhang H; Yang J; Wang X; Zhao X; Gu W; Bi Y; Peng Y; Xu X; Xia H; Li F; Xu X; Yang H; Xu G; Madsen L; Kristiansen K; Ning G; Wang W
    Nat Commun; 2017 Nov; 8(1):1785. PubMed ID: 29176714
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of gut microbiota in mediating obesity and diabetes mellitus.
    Pitocco D; Di Leo M; Tartaglione L; De Leva F; Petruzziello C; Saviano A; Pontecorvi A; Ojetti V
    Eur Rev Med Pharmacol Sci; 2020 Feb; 24(3):1548-1562. PubMed ID: 32096204
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diet, gut microbiota and cognition.
    Proctor C; Thiennimitr P; Chattipakorn N; Chattipakorn SC
    Metab Brain Dis; 2017 Feb; 32(1):1-17. PubMed ID: 27709426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypoglycemic Effect of Ginsenoside Rg5 Mediated Partly by Modulating Gut Microbiota Dysbiosis in Diabetic db/db Mice.
    Wei Y; Yang H; Zhu C; Deng J; Fan D
    J Agric Food Chem; 2020 May; 68(18):5107-5117. PubMed ID: 32307991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pelargonidin-3-
    Su H; Xie L; Xu Y; Ke H; Bao T; Li Y; Chen W
    J Agric Food Chem; 2020 Nov; 68(46):13025-13037. PubMed ID: 31322351
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of Gut Microbiota in the development of obesity and Diabetes.
    Baothman OA; Zamzami MA; Taher I; Abubaker J; Abu-Farha M
    Lipids Health Dis; 2016 Jun; 15():108. PubMed ID: 27317359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gut microorganisms as promising targets for the management of type 2 diabetes.
    Delzenne NM; Cani PD; Everard A; Neyrinck AM; Bindels LB
    Diabetologia; 2015 Oct; 58(10):2206-17. PubMed ID: 26224102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Modulation of gut microbiota by mulberry fruit polysaccharide treatment of obese diabetic db/db mice.
    Chen C; You LJ; Huang Q; Fu X; Zhang B; Liu RH; Li C
    Food Funct; 2018 Jul; 9(7):3732-3742. PubMed ID: 29995048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity.
    Tai N; Wong FS; Wen L
    Rev Endocr Metab Disord; 2015 Mar; 16(1):55-65. PubMed ID: 25619480
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gut microbiota controls adipose tissue expansion, gut barrier and glucose metabolism: novel insights into molecular targets and interventions using prebiotics.
    Geurts L; Neyrinck AM; Delzenne NM; Knauf C; Cani PD
    Benef Microbes; 2014 Mar; 5(1):3-17. PubMed ID: 23886976
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms in endocrinology: Gut microbiota in patients with type 2 diabetes mellitus.
    Allin KH; Nielsen T; Pedersen O
    Eur J Endocrinol; 2015 Apr; 172(4):R167-77. PubMed ID: 25416725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting gut microbiota as a possible therapy for diabetes.
    He C; Shan Y; Song W
    Nutr Res; 2015 May; 35(5):361-7. PubMed ID: 25818484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.
    Cao TTB; Wu KC; Hsu JL; Chang CS; Chou C; Lin CY; Liao YM; Lin PC; Yang LY; Lin HW
    Front Endocrinol (Lausanne); 2020; 11():573891. PubMed ID: 33071980
    [No Abstract]   [Full Text] [Related]  

  • 40. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus.
    Foretz M; Guigas B; Viollet B
    Nat Rev Endocrinol; 2019 Oct; 15(10):569-589. PubMed ID: 31439934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.